Silje Glenna Andersen, Henrik Sæterhagen, André Pekkola Pacheco, Are Hugo Pripp, Harald Hrubos-Strøm, Costas Papageorgiou, John Munkhaugen, Toril Dammen
{"title":"认知行为疗法对心血管疾病患者失眠的影响:系统回顾和荟萃分析","authors":"Silje Glenna Andersen, Henrik Sæterhagen, André Pekkola Pacheco, Are Hugo Pripp, Harald Hrubos-Strøm, Costas Papageorgiou, John Munkhaugen, Toril Dammen","doi":"10.5664/jcsm.11656","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objectives: </strong>Insomnia affects up to 50% of patients with cardiovascular disease and is associated with poor clinical outcomes. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia, but little is known about the effects of CBT-I in patients with established cardiovascular disease. We aimed to investigate the effects of CBT-I on insomnia symptom severity, sleep parameters, and daytime symptoms in patients with cardiovascular disease and comorbid insomnia.</p><p><strong>Methods: </strong>Medline, Embase, PsycINFO, and ClinicalTrials.gov were searched for randomized controlled and open trials up to December 2023. Study selection, data extraction, and risk of bias assessment (Cochrane's Risk of Bias 2 tool) were independently conducted by the authors. Data were meta-analyzed using random-effects models.</p><p><strong>Results: </strong>In all, 1,275 records with 5 studies fulfilled the inclusion criteria (n = 352 patients). Compared with active control groups, CBT-I significantly reduced insomnia severity posttreatment (standardized mean difference = -0.90, 95% confidence interval: -1.43, -0.37; <i>P</i> < .001), sleep onset latency, anxiety, and fatigue. Moreover, CBT-I significantly improved sleep quality (standardized mean difference = -0.77, 95% confidence interval: -1.10, -0.45; <i>P</i> < .001) and sleep efficiency (standardized mean difference = 0.68, 95% confidence interval: 0.12-1.25; <i>P</i> < .001). We regarded 3 randomized controlled trials as having low risk of bias and had some concerns with another.</p><p><strong>Conclusions: </strong>Evidence from our analyses indicated that CBT-I seems to be effective for alleviating insomnia symptoms among patients with cardiovascular disease, largely in line with the results of previous meta-analyses in patients with insomnia. The limited sample size encourages more robust evidence from high-quality, large-scale trials with long-term follow-up.</p><p><strong>Citation: </strong>Andersen SG, Sæterhagen H, Pacheco AP, et al. The effects of cognitive behavioral therapy for insomnia in patients with cardiovascular disease: a systematic review and meta-analysis. <i>J Clin Sleep Med.</i> 2025;21(7):1273-1284.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":"1273-1284"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12225284/pdf/","citationCount":"0","resultStr":"{\"title\":\"The effects of cognitive behavioral therapy for insomnia in patients with cardiovascular disease: a systematic review and meta-analysis.\",\"authors\":\"Silje Glenna Andersen, Henrik Sæterhagen, André Pekkola Pacheco, Are Hugo Pripp, Harald Hrubos-Strøm, Costas Papageorgiou, John Munkhaugen, Toril Dammen\",\"doi\":\"10.5664/jcsm.11656\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Study objectives: </strong>Insomnia affects up to 50% of patients with cardiovascular disease and is associated with poor clinical outcomes. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia, but little is known about the effects of CBT-I in patients with established cardiovascular disease. We aimed to investigate the effects of CBT-I on insomnia symptom severity, sleep parameters, and daytime symptoms in patients with cardiovascular disease and comorbid insomnia.</p><p><strong>Methods: </strong>Medline, Embase, PsycINFO, and ClinicalTrials.gov were searched for randomized controlled and open trials up to December 2023. Study selection, data extraction, and risk of bias assessment (Cochrane's Risk of Bias 2 tool) were independently conducted by the authors. Data were meta-analyzed using random-effects models.</p><p><strong>Results: </strong>In all, 1,275 records with 5 studies fulfilled the inclusion criteria (n = 352 patients). Compared with active control groups, CBT-I significantly reduced insomnia severity posttreatment (standardized mean difference = -0.90, 95% confidence interval: -1.43, -0.37; <i>P</i> < .001), sleep onset latency, anxiety, and fatigue. Moreover, CBT-I significantly improved sleep quality (standardized mean difference = -0.77, 95% confidence interval: -1.10, -0.45; <i>P</i> < .001) and sleep efficiency (standardized mean difference = 0.68, 95% confidence interval: 0.12-1.25; <i>P</i> < .001). We regarded 3 randomized controlled trials as having low risk of bias and had some concerns with another.</p><p><strong>Conclusions: </strong>Evidence from our analyses indicated that CBT-I seems to be effective for alleviating insomnia symptoms among patients with cardiovascular disease, largely in line with the results of previous meta-analyses in patients with insomnia. The limited sample size encourages more robust evidence from high-quality, large-scale trials with long-term follow-up.</p><p><strong>Citation: </strong>Andersen SG, Sæterhagen H, Pacheco AP, et al. The effects of cognitive behavioral therapy for insomnia in patients with cardiovascular disease: a systematic review and meta-analysis. <i>J Clin Sleep Med.</i> 2025;21(7):1273-1284.</p>\",\"PeriodicalId\":50233,\"journal\":{\"name\":\"Journal of Clinical Sleep Medicine\",\"volume\":\" \",\"pages\":\"1273-1284\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12225284/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Sleep Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5664/jcsm.11656\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Sleep Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5664/jcsm.11656","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
The effects of cognitive behavioral therapy for insomnia in patients with cardiovascular disease: a systematic review and meta-analysis.
Study objectives: Insomnia affects up to 50% of patients with cardiovascular disease and is associated with poor clinical outcomes. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia, but little is known about the effects of CBT-I in patients with established cardiovascular disease. We aimed to investigate the effects of CBT-I on insomnia symptom severity, sleep parameters, and daytime symptoms in patients with cardiovascular disease and comorbid insomnia.
Methods: Medline, Embase, PsycINFO, and ClinicalTrials.gov were searched for randomized controlled and open trials up to December 2023. Study selection, data extraction, and risk of bias assessment (Cochrane's Risk of Bias 2 tool) were independently conducted by the authors. Data were meta-analyzed using random-effects models.
Results: In all, 1,275 records with 5 studies fulfilled the inclusion criteria (n = 352 patients). Compared with active control groups, CBT-I significantly reduced insomnia severity posttreatment (standardized mean difference = -0.90, 95% confidence interval: -1.43, -0.37; P < .001), sleep onset latency, anxiety, and fatigue. Moreover, CBT-I significantly improved sleep quality (standardized mean difference = -0.77, 95% confidence interval: -1.10, -0.45; P < .001) and sleep efficiency (standardized mean difference = 0.68, 95% confidence interval: 0.12-1.25; P < .001). We regarded 3 randomized controlled trials as having low risk of bias and had some concerns with another.
Conclusions: Evidence from our analyses indicated that CBT-I seems to be effective for alleviating insomnia symptoms among patients with cardiovascular disease, largely in line with the results of previous meta-analyses in patients with insomnia. The limited sample size encourages more robust evidence from high-quality, large-scale trials with long-term follow-up.
Citation: Andersen SG, Sæterhagen H, Pacheco AP, et al. The effects of cognitive behavioral therapy for insomnia in patients with cardiovascular disease: a systematic review and meta-analysis. J Clin Sleep Med. 2025;21(7):1273-1284.
期刊介绍:
Journal of Clinical Sleep Medicine focuses on clinical sleep medicine. Its emphasis is publication of papers with direct applicability and/or relevance to the clinical practice of sleep medicine. This includes clinical trials, clinical reviews, clinical commentary and debate, medical economic/practice perspectives, case series and novel/interesting case reports. In addition, the journal will publish proceedings from conferences, workshops and symposia sponsored by the American Academy of Sleep Medicine or other organizations related to improving the practice of sleep medicine.